A Phase 1 interventional study of Placebo and NI-0801 in Allergic Contact Dermatitis, sponsored by Light Chain Bioscience - Novimmune SA. Completed. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-11-19.
Sponsored by Light Chain Bioscience - Novimmune SA · Phase 1 and Interventional
The purpose of the study is to assess the effect of a single dose of NI-0801 on the severity of nickel-induced allergic contact dermatitis.
52 studies on the registry are indexed under Dermatitis, Allergic Contact; 12 are open to participants now.
This study's enrollment of 22 is below the median of 48 across 40 interventional studies indexed under Dermatitis, Allergic Contact.
Browse Dermatitis, Allergic Contact studies →Light Chain Bioscience - Novimmune SA is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Placebo
Drug: NI-0801
single i.v. administration
single i.v. administration
Effect of NI-0801 administration on the severity of the cutaneous response to Nickel challenge as measured using the score system of the DKG (Deutsche Kontakt-Allergie Gruppe).
Safety and tolerability of NI-0801 as measured by the incidence and severity of treatment emergent adverse events.
No study locations are listed for this record.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dermatitis, Allergic Contact →
Light Chain Bioscience - Novimmune SA